Skip to content
Menu

Head-to-head comparison

Strut Health vs Tablet Health

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #2Desk pick
Strut Health

The same molecule as a lozenge or an injection, each priced on its own page — the only place in this ranking where the needle is genuinely optional.

$129/mo (see conditions) sema · $149/mo (see conditions) tirz · Verified August 2026

Marked down on: FDA issued Strut Health, LLC dba Strut a warning letter in February 2026; the letter is public in FDA's warning-letter database

FDAWarning letter issued to Strut Health, LLC dba Strut in February 2026. See the FDA warning-letter database.

vs
Ranked #484
Tablet Health

Tablet Health is a DTC telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral forms, with ED and NAD+ wellness lines as well.

Marked down on: States served not published — you must complete the intake quiz to learn eligibility

Strut Health takes this head-to-head with the higher Desk Score, 89/100 (B+) against 51/100 (C) for Tablet Health. Tablet Health still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Strut Health

89/100

B+

Overall

Tablet Health

51/100

C

Price transparency

93
54

State access

88
24

Molecule range

94
77

Onboarding speed

90
53

Support responsiveness

78
56

Licensing & trust

88
41

The spec sheet

FieldStrut HealthTablet Health
Semaglutide$129/mosee conditions$129/mo injectable (30-day supply on the product page; the auto-refill "as low as" badge prints the same $129, so no separate one-time price is shown; compounded) · $99/mo oral lozenge (30-day supply; same auto-refill shape)Not listed on Tablet Health's site (checked July 2026)
Tirzepatide$149/mosee conditions$149/mo injectable (30-day supply on the product page; the auto-refill "as low as" badge prints the same $149, so no separate one-time price is shown; compounded) · $199/mo oral lozenge (30-day supply; same auto-refill shape)Not listed on Tablet Health's site (checked July 2026)
Coverage49 states (not Arkansas)Not listed on Tablet Health's site (checked July 2026)
Brand-nameCompounded onlyCompounded only
Oral optionYesYes
Best forPeople whose real objection is the needle rather than the medicine, and who want every route priced before signing up.LegitScript-certified GLP-1 with an oral option and named compounders.
Desk Score89/100B+51/100C

The verdict

Desk pick — Strut Health

Strut Health takes this head-to-head with the higher Desk Score, 89/100 (B+) against 51/100 (C) for Tablet Health. Tablet Health still holds its ground where its strengths line up with yours.

Choose Strut Health if…

People whose real objection is the needle rather than the medicine, and who want every route priced before signing up.

$129/mo (see conditions) sema · $149/mo (see conditions) tirz · 49 states (not Arkansas)

FDAWarning letter issued to Strut Health, LLC dba Strut in February 2026. See the FDA warning-letter database.

Choose Tablet Health if…

LegitScript-certified GLP-1 with an oral option and named compounders.

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Strut Health · Tablet Health.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.